TITLE

Pharmacological appraisal of fixed-dose combination medicines: discussion paper

AUTHOR(S)
Snell, Eric S.
PUB. DATE
June 1982
SOURCE
Journal of the Royal Society of Medicine;Jun1982, Vol. 75 Issue 6, p457
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discuses on the combination medicines over to single products and over multiple drug regimes in Great Britain. The alleged disadvantages of the products are mostly of theoretical or doctrinal. Nearly all medicines are formulated mixture of several chemicals and a single active ingredients may be metabolized to a variety of substances with different therapeutic and toxic effects. Discrimination against combination medicine is on pharmacological grounds is questionable.
ACCESSION #
22778210

 

Related Articles

  • Developing and Using Therapeutics for Emerging Infections. McCune, Jeannine S.; Reynolds, Kellie S. // Clinical Pharmacology & Therapeutics;Oct2015, Vol. 98 Issue 4, p346 

    This issue of Clinical Pharmacology & Therapeutics focuses on emerging infections. The outbreaks of the vaccine-preventable diseases (e.g., measles) and the emerging pathogens (e.g., Ebola) show us how small the world has become. These outbreaks also show the pressing need for effective public...

  • History of clinical pharmacology in Korea. Sang-Goo Shin // Translational & Clinical Pharmacology;Dec2014, Vol. 22 Issue 2, p43 

    The author recounts the history of clinical pharmacology in South Korea. Topics discussed include the establishment of in-house research institute to foster new drug development capabilties by Korean pharmaceutical companies in the 1980s and the growing interest of Korean medical societies on...

  • Battle of Biosimilars. O'Donnell, Peter // Applied Clinical Trials;Feb2006, Vol. 15 Issue 2, p38 

    The article focuses on the establishment of a working party on biosimilar medicinal products by the European Medicines Agency in London, England. The commission is developing a new guideline on non-clinical and clinical issues in connection to biosimilar medicinal products comprising...

  • What Happened to the Modeling and Simulation Revolution? Bonate, P L // Clinical Pharmacology & Therapeutics;Oct2014, Vol. 96 Issue 4, p416 

    The article discusses the condition of modeling and simulation that is not as influential as in drug development due to poor model communicators and insulated stories of success. It cites the author's presentation discussing about the challenges facing pharmacometricians. It mentions the poor...

  • Editoral. Tatiana, Foltánová // Acta Facultatis Pharmaceuticae Universitatis Comenianae;2012 Supplement 6, Vol. 59, p5 

    A letter is presented to the followers of Clinical Pharmacy in the Slovak republic.

  • Klinisch-pharmakologische Aspekte zur Beschleunigung des Drug Development-Prozesses von der Präklinik zur Klinik. Kuhlmann, Jochen // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Jun2004, Vol. 54 Issue 6, p307 

    Clinical-pharmacological Aspects to Accelerate the Development Process from the Preclinical to the Clinical Phase / 2nd Communication: Promising strategies To improve the transition from research to development a critical evaluation of the individual project by research and disease area teams is...

  • Improving the Drug Development Process. Djulbegovic, Benjamin; Hozo, Iztok; Ioannidis, John P. A. // JAMA: Journal of the American Medical Association;1/22/2014, Vol. 311 Issue 4, p355 

    The authors stress the need to improve the drug development process in the U.S. They claim that the preclinical screening evaluation being used in animals and cell cultures may not be efficient and might not be informative about what will happen in humans. They suggest that randomized trials...

  • Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice. Huang, S.-M.; Temple, R. // Clinical Pharmacology & Therapeutics;Sep2008, Vol. 84 Issue 3, p287 

    The author reflects on the consideration and impact of ethnic factors in the global development of drugs, clinical practice, and regulatory review in the U.S. He argues that both extrinsic and intrinsic ethnic factors in the different regions and populations affect exposure and drug response as...

  • Adolescents in Clinical Trials. Kapogiannis, B. G.; Mattison, D. R. // Clinical Pharmacology & Therapeutics;Dec2008, Vol. 84 Issue 6, p655 

    Drug development is a lengthy, costly, and complex process, with clinical trials essential for characterizing dosing, safety, and efficacy in treated populations. After regulatory approval, aggressive marketing ensures that most drugs are used by a broad spectrum of ages, genders, races, and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics